DGX vs TRU · P/E 22, rev $5.94B vs P/E 19, rev $4.58B
Quest Diagnostics Incorporated (DGX) versus TransUnion (TRU) — a side-by-side from cached financials, not a winner call.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
TransUnion (TRU) is a financial data & stock exchanges company listed on NYSE.
Latest reported DGX revenue for 2026-06-30 was $5.94B. Net income was $572.0M. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
Latest reported TRU revenue for 2025-12-31 was $4.58B. Net income was $455.4M. Revenue was up 9.4% from 2024-12-31 to 2025-12-31. TRU currently screens at market cap $13.41B and trailing P/E 19.3.
DGX currently screens at market cap $19.94B and trailing P/E 22.4. TRU currently screens at market cap $13.41B and trailing P/E 19.3.
Not investment advice. Open the DGX and TRU stock pages for the full models.
Not investment advice.